NasdaqGS:BLUE

Stock Analysis Report

Executive Summary

bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer.


Snowflake Analysis

Flawless balance sheet and fair value.


Similar Companies

Share Price & News

How has bluebird bio's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: BLUE's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-1.7%

BLUE

5.2%

US Biotechs

10.5%

US Market


1 Year Return

-69.6%

BLUE

0.05%

US Biotechs

-11.5%

US Market

Return vs Industry: BLUE underperformed the US Biotechs industry which returned 0% over the past year.

Return vs Market: BLUE underperformed the US Market which returned -11.5% over the past year.


Shareholder returns

BLUEIndustryMarket
7 Day-1.7%5.2%10.5%
30 Day-28.5%-6.5%-15.4%
90 Day-46.0%-8.7%-21.4%
1 Year-69.6%-69.6%0.8%0.05%-9.6%-11.5%
3 Year-47.4%-47.4%8.9%6.2%12.6%5.4%
5 Year-59.7%-59.7%-6.2%-10.4%32.8%18.1%

Price Volatility Vs. Market

How volatile is bluebird bio's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is bluebird bio undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: BLUE ($47.77) is trading below our estimate of fair value ($284.51)

Significantly Below Fair Value: BLUE is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: BLUE is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: BLUE is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate BLUE's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: BLUE is good value based on its PB Ratio (2.1x) compared to the US Biotechs industry average (2.5x).


Next Steps

Future Growth

How is bluebird bio forecast to perform in the next 1 to 3 years based on estimates from 21 analysts?

20.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: BLUE is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: BLUE is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: BLUE is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: BLUE's revenue (49.7% per year) is forecast to grow faster than the US market (7.3% per year).

High Growth Revenue: BLUE's revenue (49.7% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if BLUE's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has bluebird bio performed over the past 5 years?

-39.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: BLUE is currently unprofitable.

Growing Profit Margin: BLUE is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: BLUE is unprofitable, and losses have increased over the past 5 years at a rate of -39.4% per year.

Accelerating Growth: Unable to compare BLUE's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BLUE is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (22%).


Return on Equity

High ROE: BLUE has a negative Return on Equity (-61.45%), as it is currently unprofitable.


Next Steps

Financial Health

How is bluebird bio's financial position?


Financial Position Analysis

Short Term Liabilities: BLUE's short term assets ($1.2B) exceed its short term liabilities ($223.6M).

Long Term Liabilities: BLUE's short term assets ($1.2B) exceed its long term liabilities ($218.9M).


Debt to Equity History and Analysis

Debt Level: BLUE is debt free.

Reducing Debt: BLUE has not had any debt for past 5 years.


Balance Sheet

Inventory Level: BLUE has a low level of unsold assets or inventory.

Debt Coverage by Assets: BLUE's debt is not covered by short term assets (assets are -4.0538518727078E+16x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: BLUE has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: BLUE has sufficient cash runway for 1.5 years if free cash flow continues to reduce at historical rates of -40.9% each year.


Next Steps

Dividend

What is bluebird bio's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate BLUE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate BLUE's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BLUE's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BLUE's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of BLUE's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.0yrs

Average management tenure


CEO

Nick Leschly (46yo)

9.5s

Tenure

US$23,962,220

Compensation

Mr. Nick Leschly has been the Chief Executive Officer and President at bluebird bio, Inc. (alternate name Genetix Pharmaceuticals Inc.) since September 2010. Mr. Leschly served as Interim President at blue ...


CEO Compensation Analysis

Compensation vs Market: Nick's total compensation ($USD23.96M) is above average for companies of similar size in the US market ($USD5.51M).

Compensation vs Earnings: Nick's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Nick Leschly
President9.5yrsUS$23.96m0.33% $8.8m
Jason Cole
Chief Operating & Legal Officer and Secretary1.08yrsUS$5.37m0.028% $738.5k
Philip Gregory
Chief Scientific Officer4.75yrsUS$8.68m0.024% $633.9k
David Davidson
Chief Medical Officer8.08yrsUS$9.27m0.024% $646.6k
William Baird
Chief Financial Officer1.08yrsno data0.0045% $119.3k
Kory Wentworth
VP of Finance2.25yrsno data0.0037% $98.8k
Derek Adams
Chief Technology & Manufacturing Officer3yrsno datano data
Ingrid Goldberg
Vice President of Investor Relationsno datano datano data
Kathleen Wilkinson
Chief People Officer2.83yrsno datano data
Alison Finger
Chief Commercial Officer4.58yrsno data0.020% $523.1k

3.0yrs

Average Tenure

47yo

Average Age

Experienced Management: BLUE's management team is considered experienced (3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Nick Leschly
President9.5yrsUS$23.96m0.33% $8.8m
Philip Reilly
Member of Scientific Advisory Board9yrsno datano data
Philippe Leboulch
Co-Chair of Scientific Advisory Boardno datano datano data
Stephen Goff
Member of Scientific Advisory Board9yrsno datano data
Daniel Lynch
Chairman8.83yrsUS$1.02m0.0076% $200.6k
Mark Vachon
Independent Director5.67yrsUS$717.70k0.0018% $47.8k
Mitchell Finer
Member of Scientific Advisory Board4.67yrsUS$1.57mno data
Malcolm Brenner
Member of Scientific Advisory Board9yrsno datano data
David Schenkein
Independent Director6.92yrsUS$720.95k0.0075% $199.5k
Christof von Kalle
Member of Scientific Advisory Board9yrsno datano data

9.0yrs

Average Tenure

61yo

Average Age

Experienced Board: BLUE's board of directors are considered experienced (9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: BLUE insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 6.1%.


Top Shareholders

Company Information

bluebird bio, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: bluebird bio, Inc.
  • Ticker: BLUE
  • Exchange: NasdaqGS
  • Founded: 1992
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$2.657b
  • Shares outstanding: 55.61m
  • Website: https://www.bluebirdbio.com

Number of Employees


Location

  • bluebird bio, Inc.
  • 60 Binney Street
  • Cambridge
  • Massachusetts
  • 2142
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BLUENasdaqGS (Nasdaq Global Select)YesCommon SharesUSUSDJun 2013
BLEDB (Deutsche Boerse AG)YesCommon SharesDEEURJun 2013
0HOHLSE (London Stock Exchange)YesCommon SharesGBUSDJun 2013
BLEBRSE (Berne Stock Exchange)YesCommon SharesCHCHFJun 2013
BLUE *BMV (Bolsa Mexicana de Valores)YesCommon SharesMXMXNJun 2013

Biography

bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates in severe genetic diseases include LentiGlobin, which is in various clinical studies for the treatment of transfusion-dependent ß-thalassemia and severe sickle cell disease; and Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder. The company’s product candidates in oncology include bb2121 and bb21217, which are chimeric antigen receptor T (CAR T) cell product candidates for the treatment of multiple myeloma. It has a strategic collaboration with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology; and Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize various immune cell therapies for cancer. The company also has collaborations with Medigene AG to discover T cell receptor (TCR) product candidates in the field of cancer; Gritstone Oncology, Inc. to discover TCR product candidates in the field of cancer; TC BioPharm Limited to research and develop gamma delta CAR T cells directed at hematologic and solid tumor targets; and Novo Nordisk A/S to develop in vivo genome editing treatments for genetic diseases. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/03/28 02:49
End of Day Share Price2020/03/27 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.